viatris glp-1 receptor agonist medications Novo Nordisk suffers Wegovy defeat to in patent court GLP-1 Receptor Agonists as Treatments
Description
2023;72(Supplement_1) doi: 10.2337/db23-128-OR
We will review the data, relative risk, and strategies for mitigating adverse events in people using GLP-1 medicines, said Dr
Future challenges: Advancements have been made, but some key issues still remain
It hasnt been studied in patients with severe gastrointestinal disease and isnt recommended in these patients
[DOI] [PubMed] [Google Scholar] 30.Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, Zhang Y, Ji L, Wang J, Shi L
Contact [email protected] for any questions or corrections.
